- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events reported to date - - Data from this non-MTS cohort, ...
Neurona Therapeutics and UCSF researchers have developed and characterized a cell therapy alternative to treat drug-resistant mesial temporal lobe epilepsy (MTLE), the most common type of focal ...
The researchers of a single-center study found that the relationships between epilepsy and autoimmune diseases may be a result of the different etiopathogenetic mechanisms that underly seizure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback